source
- Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pendingPharvaris announced that its oral bradykinin B2 receptor antagonist, deucrictibant, met the primary goal in a second phase 3 study. The trial, called CHAPTER-3, enrolled 85 patients with three for…
- Benelux’s strong science base eyed for biotech scaling despite funding gapsBelgium and the Netherlands have built some of Europe’s strongest life‑science ecosystems, anchored by leading research institutions and a growing pool of biotech talent. Early‑stage capital remai…